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Transplant Outcomes
Median OS (years) 5.9548
Acute GVHD Grade:
0-2 15 (68.2)
3-5 7 (31.8)
Chronic GVHD:
None 10 (50)
Limited 4 (20)
Extensive 6 (30)
NRM at 1 year 7 (35%)
Median Survival (years)
per GVHD prophylaxis regimen:
Calcineurin inhibitor/MTX 14.4
Calcineurin inhibitor/MYC 2.3241
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Background: Allogeneic bone marrow transplantation (allo-
BMT) in Multiple Myeloma (MM) offers a potential curativeTable 1
Patient Characteristics (N ¼ 22)
N (%)
Median Age (years) 49.5
Sex:
Male 8 (36)
Myeloma Subtype:
Kappa light chain 2 (9.1)
Lambda light chain 3 (13.6)
IgA 3 (13.6)
IgG 13 (59.1)
Minimally secretory 1 (4.5)
DSS:
I 3 (13.6)
II 3 (13.6)
III 16 (72.7)
Response prior to transplant:
CR 2 (9.1)
PR1 4 (18.2)
PR2+ 8 (36.4)
SD/MR 5 (22.7)
PD 2 (9.1)
Unknown 1 (4.5)
Donor:
MUD 3 (13.6)
MRD 19 (86.3)
HLA-matching:
9/10 10 (45.5)
10/10 12 (54.5)
Conditioning regimen:
FLU/CY 1 (4.5)
FLU/MEL 8 (36.4)
FLU/MEL/ATG 2 (9.1)
MEL/TBI 9 (40.9)
TBI 2 (9.1)
Source of Stem Cells:
Peripheral Blood 8 (36.4)
Bone Marrow 14 (63.6)
GVHD prophylaxis:
CYA 1 (4.5)
CYA/MTX 8 (36.4)
CYA/MYC 2 (9.1)
TAC/MTX 2 (.1)
TAC/MYC 9 (40.9)strategy. This study was undertaken to determine outcomes
of patients with MM undergoing allogeneic BMT at Temple
University Hospital over the past 18 years.
Methods: We retrospectively reviewed our clinical database
for patients with a diagnosis of MM who underwent an allo-
BMT between 1994 to present. We reviewed the following
variables: Age, sex, myeloma subtype and stage, remission
status prior to transplant, stem cell source and degree of
donor matching, conditioning regimen, GVHD prophylaxis.
Outcome measures included overall survival, non-relapsed
mortality (NRM), and acute and chronic GVHD.
Results: Patient characteristics are summarized in the Table
1. The median age was 49.5 years, 72.7% had DSS III, 68% had
either at least PR2, PD or SD/MR, and 86.3% had a MRD
transplant. The outcomes are summarized in Table 2. The
median actuarial overall survival for the cohort is 5.95
years and the ten year actuarial survival for the cohort is
34%. Median survival with a Calcineurin inhibitor (CUI) and
methotrexate combination for GVHD prophylaxis was 14.4
years, as compared to 2.2 years for CUI and mycophenolate
based regimens (P ¼ .05). The relapse rate for the cohort
was 31.8%, Grade 3 or more acute GVHD developed in
31.8%, while extensive chronic GVHD occurred in 30% of
the patients.
Conclusion: Allogeneic transplantation is a reasonable
strategy in patients with MM which can lead to long-term
survival. Patients receiving GVHD prophylaxis with a CUI and
Methotrexate experienced superior survival compared to
those receiving a CUI and mycophenolate based regimen.
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Various preparative regimens are utilized for autologous
transplantation in patients with relapsed diffuse large cell
lymphoma, including TBI based regimens. The most
commonly used regimen includes Ara-C + Etoposide +
Melphalan + BCNU (BEAM). At our institution the ablative
regimen utilized includes Cytoxan 7200 mg/m2, BCNU
400mg/m2 and Etoposide 2400mg/m2 (Augmented CBV).
